Celldex Therapeutics, Inc. (CLDX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 1.5M 3M 4.5M Q3 '16: 2.2M Q4 '16: 1.9M Q1 '17: 1.5M Q2 '17: 3.8M Q3 '17: 3.9M Q4 '17: 3.5M Q1 '18: 4.1M Q2 '18: 2.8M Q3 '18: 941K Q4 '18: 1.8M Q1 '19: 1.4M Q2 '19: 715K Q3 '19: 546K Q4 '19: 887K Q1 '20: 2.7M Q2 '20: 236K Q3 '20: 668K Q4 '20: 3.8M Q1 '21: 685K Q2 '21: 3.5M Q3 '21: 153K Q4 '21: 334K Q1 '22: 174K Q2 '22: 163K Q3 '22: 407K Q4 '22: 1.6M Q1 '23: 967K Q2 '23: 268K Q3 '23: 1.5M Q4 '23: 4.1M Q1 '24: 156K Q2 '24: 2.5M Q3 '24: 3.2M Q4 '24: 1.2M Q1 '25: 695K Q2 '25: 730K Q3 '25: 0 Q4 '25: 121K Q1 '26: 15K Q2 '26: 22K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '16: -30M Q4 '16: -34.9M Q1 '17: -35.1M Q2 '17: -28.9M Q3 '17: -32M Q4 '17: -25.5M Q1 '18: -119.7M Q2 '18: -16.9M Q3 '18: -7.8M Q4 '18: -12.1M Q1 '19: -17.9M Q2 '19: -12.3M Q3 '19: -11.8M Q4 '19: -13M Q1 '20: -12.9M Q2 '20: -11.4M Q3 '20: -14.3M Q4 '20: -24.8M Q1 '21: -16.6M Q2 '21: -13.4M Q3 '21: -20.8M Q4 '21: -20.3M Q1 '22: -23.3M Q2 '22: -36.4M Q3 '22: -27.7M Q4 '22: -27.9M Q1 '23: -32.5M Q2 '23: -33.2M Q3 '23: -41.2M Q4 '23: -47.6M Q1 '24: -40.6M Q2 '24: -46.3M Q3 '24: -52.1M Q4 '24: -56M Q1 '25: -62.7M Q2 '25: -63.9M Q3 '25: -73.6M Q4 '25: -87.2M Q1 '26: -84.4M Q2 '26: -80.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '16: -29.6M Q4 '16: -32.3M Q1 '17: -34.3M Q2 '17: -28.6M Q3 '17: -26.4M Q4 '17: -3.8M Q1 '18: -118.1M Q2 '18: -16.4M Q3 '18: -7.2M Q4 '18: -9.4M Q1 '19: -17.2M Q2 '19: -11.8M Q3 '19: -11.4M Q4 '19: -10.4M Q1 '20: -12.6M Q2 '20: -11M Q3 '20: -14.2M Q4 '20: -21.9M Q1 '21: -16.5M Q2 '21: -13.4M Q3 '21: -20.5M Q4 '21: -20.1M Q1 '22: -23.1M Q2 '22: -36M Q3 '22: -26.8M Q4 '22: -26.5M Q1 '23: -29.4M Q2 '23: -30.5M Q3 '23: -38.3M Q4 '23: -43.3M Q1 '24: -32.8M Q2 '24: -35.8M Q3 '24: -42.1M Q4 '24: -47.1M Q1 '25: -53.8M Q2 '25: -56.6M Q3 '25: -67M Q4 '25: -81.3M Q1 '26: -78.7M Q2 '26: -73.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '16: -24M Q4 '16: -20.3M Q1 '17: -35.3M Q2 '17: -20.8M Q3 '17: -24.4M Q4 '17: -19.5M Q1 '18: -28M Q2 '18: -17.4M Q3 '18: -14.4M Q4 '18: -15.4M Q1 '19: -13.2M Q2 '19: -11M Q3 '19: -11.1M Q4 '19: -11M Q1 '20: -12.1M Q2 '20: -11.2M Q3 '20: -11.9M Q4 '20: -5.2M Q1 '21: -18.1M Q2 '21: -11.9M Q3 '21: -16.4M Q4 '21: -14.5M Q1 '22: -24.5M Q2 '22: -22.2M Q3 '22: -35.2M Q4 '22: -21.8M Q1 '23: -28.6M Q2 '23: -27.2M Q3 '23: -19M Q4 '23: -32.5M Q1 '24: -40.6M Q2 '24: -29.3M Q3 '24: -55.3M Q4 '24: -32.5M Q1 '25: -54.4M Q2 '25: -44M Q3 '25: -48.6M Q4 '25: -63.9M Q1 '26: -65.6M Q2 '26: -57.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '16: -24.8M Q4 '16: -21M Q1 '17: -35.6M Q2 '17: -21.7M Q3 '17: -24.6M Q4 '17: -19.7M Q1 '18: -28.3M Q2 '18: -17.7M Q3 '18: -14.4M Q4 '18: -15.6M Q1 '19: -13.4M Q2 '19: -11.3M Q3 '19: -11.3M Q4 '19: -11.1M Q1 '20: -12.3M Q2 '20: -12.1M Q3 '20: -12M Q4 '20: -5.5M Q1 '21: -18.7M Q2 '21: -12.1M Q3 '21: -16.6M Q4 '21: -14.9M Q1 '22: -25.1M Q2 '22: -22.9M Q3 '22: -35.5M Q4 '22: -22M Q1 '23: -29.2M Q2 '23: -27.6M Q3 '23: -19.1M Q4 '23: -33.2M Q1 '24: -41M Q2 '24: -29.6M Q3 '24: -55.9M Q4 '24: -33.2M Q1 '25: -54.6M Q2 '25: -44.7M Q3 '25: -49.1M Q4 '25: -65.2M Q1 '26: -67.2M Q2 '26: -60.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '10: 31.8M Q3 '10: 31.9M Q1 '11: 32M Q2 '11: 37.5M Q3 '11: 44.1M Q1 '12: 50.1M Q1 '21: 39.6M Q2 '21: 39.6M Q3 '21: 45.5M Q1 '22: 46.7K Q2 '22: 46.8K Q3 '22: 46.9K Q1 '23: 47.2K Q2 '23: 47.3K Q3 '23: 47.3K Q1 '24: 58.9K Q2 '24: 66K Q3 '24: 66.3K Q1 '25: 66.4M Q2 '25: 66.4M Q3 '25: 66.4K Q1 '26: 66.6M Q2 '26: 77.8M Q3 '10 Q3 '11 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q1 '12: -1.10 Q2 '12: -1.06 Q3 '12: -1.04 Q4 '12: -1.02 Q1 '13: -0.98 Q2 '13: -0.99 Q3 '13: -1.03 Q4 '13: -1.03 Q1 '14: -1.13 Q2 '14: -1.21 Q3 '14: -1.23 Q4 '14: -1.32 Q1 '15: -1.32 Q2 '15: -1.33 Q3 '15: -1.34 Q4 '15: -1.31 Q1 '16: -1.33 Q2 '16: -1.32 Q3 '16: -1.29 Q4 '16: -1.26 Q1 '17: -1.19 Q2 '17: -1.10 Q3 '17: -1.01 Q4 '17: -1.13 Q1 '18: -13.46 Q2 '18: -14.90 Q3 '18: -15.36 Q4 '18: -15.75 Q1 '19: -4.54 Q2 '19: -3.71 Q3 '19: -3.80 Q4 '19: -3.63 Q1 '20: -2.96 Q2 '20: -2.62 Q3 '20: -2.23 Q4 '20: -2.14 Q1 '21: -1.83 Q2 '21: -1.67 Q3 '21: -1.76 Q4 '21: -1.64 Q1 '13 Q2 '14 Q3 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.